Vycor Medical Q1 2026 revenue up 5% to $458,540; turns to operating profit of $45,808

VYCOR MEDICAL INC

2026-Q1 EPS reported $0.00 revenue$458,540

Revenue $458,540 (+5% YoY); Vycor Medical division contributed $440,441.
Operating profit of $45,808 vs operating loss of $(12,806) in Q1 2025.
Non-GAAP operating profit $59,788, up from $20,388 YoY; cash expenses down to $315,365.
Gross margin steady at 82% for Vycor Medical; two new peer-reviewed VBAS studies published.
NovaVision revenue $18,099, still in development stage.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VYCOR MEDICAL INC reported the three months ended March 31, 2026 results: revenue $458,540.

Period: the three months ended March 31, 2026
Revenue: $458,540
Result: reported results

Exact text from the filing

the traditional blade retractor group, implying safer tumor resection using VBAS. Financial Results For the three months ended March 31, 2026, the Company reported revenue of $458,540, an increase of $22,162 (or 5%) over the 2025 period. The Vycor Medical division (VBAS) generated revenue of $440,441, an increase of $21,921 (or 5%) over the 2025 period. Most of

View on SEC.gov

Browse all earnings releases →

VYCOR MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001493152-26-023666

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.